Modalis Therapeutics Corporation announced it will regain full development and commercial rights to MDL-201 and MDL-202 from Astellas Pharma Inc. It also reveals that target indications for the products are Duchene Muscular Dystrophy (DMD) and Myotonic Dystrophy type 1 (DM1), respectively. Modalis is also announcing a sharpened strategic focus, to prioritize its investments in the most promising programs: MDL-101, the lead program in its pipeline which has completed preIND and is moving forward to the clinic for LAMA2-CMD, and MDL-202 for DM1. This matter shall have a minor impact on cost compared with that of the whole R&D for the fiscal year ending December 31, 2023, and the following years.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
68 JPY | -4.23% | +4.62% | -45.16% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,536 JPY | -1.73% | +0.89% | 17.85B | ||
68 JPY | -4.23% | +4.62% | 16.65M | ||
1st Jan change | Capi. | |
---|---|---|
-45.16% | 16.65M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.22% | 21.83B | |
-10.95% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- 4883 Stock
- News Modalis Therapeutics Corporation
- Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc